ArmaGen Technologies, Inc. Receives Notice Of Allowance For U.S. Patent Covering Novel Investigational Therapy For Hunter Syndrome
6/17/2014 10:15:00 AM
CALABASAS, Calif.--(BUSINESS WIRE)--ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders, announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent claiming the composition of AGT-182, a novel enzyme replacement therapy (ERT) under development for the treatment of neurological complications in patients with Hunter syndrome. The patent, when issued, will be in force until at least 2030.
Help employers find you! Check out all the jobs and post your resume.
comments powered by